Desotop15 gm

Desotop is a low-potency (Class VI) topical corticosteroid used for the relief of inflammation and pruritus (itching) associated with corticosteroid-responsive skin conditions.

Established / FDA-approved uses

• Atopic dermatitis (eczema), including in infants and young children
• Contact dermatitis and other inflammatory, pruritic dermatoses that respond to topical corticosteroids
• Seborrheic dermatitis

Guideline-supported / commonly used for

• Mild plaque psoriasis, particularly on sensitive areas such as the face, skin folds (intertriginous areas), and genital area, where higher-potency steroids are usually avoided
• Inflammatory skin conditions in young children, given the lower potency and relatively favorable safety profile compared with higher-potency corticosteroids

Desotop is intended for short-term, intermittent use on limited body surface areas rather than as a continuous long-term therapy.

Each formulation contains Desonide as the active ingredient, typically at a strength of 0.05% w/w, formulated as a cream, ointment, lotion, gel, or foam for topical application. Inactive ingredients (emollient/vehicle base, preservatives) vary by dosage form and manufacturer.

Desotop is a synthetic, non-fluorinated corticosteroid classified as a low-potency (Group VI) topical steroid on the standard potency scale. It is applied directly to the skin to reduce inflammation, redness, swelling, and itching associated with a range of dermatologic conditions.

Because of its low potency, Desotop is frequently chosen for use on thin-skinned or sensitive areas (face, eyelids, skin folds, groin) and for use in infants and young children, where the risk of local and systemic corticosteroid side effects from more potent agents is higher.

Desotop belongs to the therapeutic class of topical corticosteroids, specifically classified as a low-potency (Class/Group VI) topical corticosteroid.

Desonide exerts its therapeutic effect by binding to intracellular glucocorticoid receptors in skin cells. This receptor-steroid complex translocates to the nucleus and modulates gene transcription, leading to:

• Induction of lipocortin (annexin A1), which inhibits phospholipase A2 and thereby reduces the release of arachidonic acid and its downstream inflammatory mediators (prostaglandins, leukotrienes)
• Suppression of inflammatory cell migration and cytokine release
• Local vasoconstriction, reducing erythema and edema
• Reduced epidermal cell proliferation, which helps in conditions such as psoriasis

Systemic absorption of Desonide through intact skin is generally low, but it can increase with use on inflamed or broken skin, application under occlusion, use over large body surface areas, or prolonged/extensive use, particularly in infants and young children who have a higher skin-surface-area-to-body-weight ratio.

• Wash and dry hands before and after application, unless the hands are the area being treated
• Apply a thin film of Desotop to the affected area only and gently rub in
• Avoid contact with the eyes, mouth, and mucous membranes
• Do not cover the treated area with a bandage, dressing, or diaper (occlusion) unless specifically directed by a physician, as this increases systemic absorption
• Do not apply Desotop to open wounds or broken skin unless instructed by a physician
• Do not use more often or for longer than prescribed

Because systemic absorption of topically applied Desotop is generally low when used as directed, clinically significant drug-drug interactions are uncommon. Points to note:

• Concomitant use of other topical corticosteroids or topical products on the same skin area may increase local irritation or cumulative corticosteroid exposure; avoid combining multiple corticosteroid-containing products without medical advice.
• Use of occlusive dressings or application to large/inflamed areas together with other agents that enhance skin penetration can increase systemic absorption of Desotop and the risk of systemic corticosteroid effects (see Precautions and Warnings).

Common (local) side effects

• Stinging, burning, or itching at the application site
• Dryness or irritation of the skin
• Acne-like eruptions or folliculitis
• Local skin atrophy (thinning), striae (stretch marks), and telangiectasia (visible small blood vessels) with prolonged use, particularly on thin-skinned areas
• Hypopigmentation (lightening) or hyperpigmentation of the treated skin

Uncommon / systemic effects (usually with prolonged, extensive, or occlusive use)

• Hypothalamic-pituitary-adrenal (HPA) axis suppression
• Cushingoid features (rounded face, weight gain) with significant systemic absorption
• Hyperglycemia
• Secondary infection at the application site

Patients should discontinue Desotop and seek medical advice if the treated condition worsens or if signs of infection or systemic effects develop.

Pregnancy: Adequate, well-controlled studies of Desotop in pregnant women are lacking. Desotop should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Use on large body surface areas or for prolonged periods during pregnancy should be avoided. Consult a physician before use.

Lactation: It is not known whether topical Desotop is excreted in human milk in clinically significant amounts. As a precaution, avoid applying Desotop directly to the breast or nipple area before breastfeeding, and use the minimum effective amount elsewhere. Consult a physician before use while breastfeeding.

• Use the lowest effective potency and the shortest duration of Desotop necessary to control symptoms.
• Prolonged or extensive use, especially under occlusion or over large body surface areas, can lead to systemic corticosteroid absorption and effects, including HPA-axis suppression; this risk is higher in infants and young children because of their greater skin-surface-area-to-body-weight ratio.
• Local skin atrophy, striae, and telangiectasia can occur even with a low-potency steroid such as Desotop if used for prolonged periods, particularly on thin-skinned areas (face, groin, skin folds).
• Avoid prolonged use on the face or groin without specific medical guidance, despite the relatively favorable safety profile of Desotop compared with higher-potency corticosteroids.
• Discontinue Desotop and seek medical evaluation if the treated condition worsens or shows signs of secondary infection.
• Desotop is not intended for continuous, long-term use without periodic medical reassessment.
• Avoid contact with eyes; long-term ophthalmic exposure to topical corticosteroids has been associated with cataracts and glaucoma.

Topical overdose of Desotop is unlikely from a single application but excessive, prolonged, or extensive use can lead to systemic corticosteroid effects, including HPA-axis suppression and Cushingoid features (see Side Effects and Precautions). If Desotop is accidentally ingested, or if signs of systemic corticosteroid toxicity appear, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not freeze.

Pediatric patients

Desotop may be used in children 3 months of age and older under medical supervision, using the minimum amount and shortest duration needed, because children have a higher skin-surface-area-to-body-weight ratio and are more susceptible to systemic absorption and HPA-axis suppression. Safety and efficacy in infants younger than 3 months have not been established.

Elderly patients

Elderly patients often have thinner skin and may be at greater risk of local atrophy, bruising, or skin tearing with prolonged use of Desotop; use with caution and for the minimum necessary duration.

Hepatic/renal impairment

No specific dose adjustment of Desotop has been established for hepatic or renal impairment, as systemic exposure from topical use is generally minimal when used as directed.

Treatment with Desotop cream, ointment, or lotion is generally limited to a maximum of 2 weeks, and gel or foam formulations to a maximum of 4 weeks, unless a physician directs otherwise. Desotop is not intended for continuous, uninterrupted long-term use; treatment should be reassessed periodically by a physician, especially if longer or repeated courses are being considered.

Desonide is classified as a topical corticosteroid, specifically a low-potency (Group/Class VI) topical corticosteroid, in the non-fluorinated corticosteroid subgroup.

Desonide diffuses across the skin cell membrane and binds to cytoplasmic glucocorticoid receptors. The activated receptor complex moves into the nucleus and regulates the transcription of anti-inflammatory and anti-proliferative proteins, including lipocortin, which inhibits phospholipase A2 and reduces production of arachidonic acid-derived inflammatory mediators (prostaglandins and leukotrienes). This results in local vasoconstriction, reduced capillary permeability, suppressed inflammatory cell infiltration, and decreased epidermal cell turnover, collectively reducing erythema, edema, and pruritus in the treated skin.

C

Desotop cream, ointment, lotion, gel, and foam (0.05%) are approved for use in pediatric patients 3 months of age and older for corticosteroid-responsive dermatoses, under medical supervision. Safety and efficacy of Desotop have not been established in infants younger than 3 months.

Because children have a larger skin-surface-area-to-body-weight ratio than adults, they are more susceptible to systemic absorption and adverse effects (including HPA-axis suppression, growth retardation, and Cushingoid features) following topical corticosteroid use. Desotop should therefore be used in children at the minimum effective amount, for the shortest duration necessary, and use of occlusive dressings or diapers over treated areas should be avoided unless specifically directed by a physician.